BBO-8520 Preclinical Data Published in Cancer Discovery Supports the Potential for the First-in-Class Molecule to Provide Therapeutic Benefit in KRASG12C Mutant Tumors December 10, 2024
AAVantgarde presents safety data of the first two subjects dosed in the LUCE-1 study, evaluating AAVB-081 (Dual-AAV) in retinitis pigmentosa related to Usher Syndrome type 1B December 9, 2024
Be Biopharma Unveils BeCoMe-9 Trial and Presents on Versatile B Cell Medicines Platform December 9, 2024
TScan Therapeutics Named a Top Place to Work by The Boston Globe for Three Consecutive Years December 6, 2024
AAVantgarde Bio Announces FDA Orphan Drug Designation for AAVB-081 for the Treatment of Usher Syndrome Type 1B Retinitis Pigmentosa December 2, 2024
Rectify Pharma Presents Preclinical Data Supporting Development of Lead Candidate RTY-694 November 19, 2024
